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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on synthetic L-ergothioneine, marketed as
Ergoneine®, as a novel food submitted pursuant to Regulation (EC) No 258/97 of the European
Parliament and of the Council. The novel food, synthetic L-ergothioneine, is produced by a one-pot
patented manufacturing process. Chemically, L-ergothioneine is a derivative of thiolhistidine, and it is
naturally present in a number of foodstuffs such as mushrooms, some varieties of black and red
beans, offal and cereals. The production process for the novel food is sufficiently described and does
not raise concerns about the safety of the novel food. The information on the composition,
specifications, batch-to-batch variability and stability of the novel food is sufficient and does not raise
safety concerns. The applicant intends to use the novel food in quantities of up to 5 mg per serving in
alcohol-free beverages, cereal bars, milk, fresh dairy products and chocolate. The applicant also
proposes to provide the novel food as a food supplement, with a daily dose of up to 30 mg/day for
adults and 20 mg/day for children. The target population is children above 3 years of age and the
general adult population, except pregnant and breastfeeding women. Considering the NOAEL of
800 mg/kg bw per day, which was based on two subchronic toxicity studies in rats, and the maximum
estimated intake levels for L-ergothioneine from all sources, the Panel concludes that the margins of
safety of 470 for adults (except pregnant and breastfeeding women) and of 216 for children above
3 years of age are sufficient. The Panel concludes that the novel food, synthetic L-ergothioneine
(marketed as Ergoneine®), is safe under the intended conditions of use as specified by the applicant.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on synthetic L-ergothioneine, marketed as
Ergoneine®, as a novel food (NF) submitted pursuant to Regulation (EC) No 258/97 of the European
Parliament and of the Council. The assessment follows the methodology set out in Commission
Recommendation 97/618/EC of 29 July 1997. The assessment is based on the data supplied in the
original application, the initial assessment by the competent authority of France, the concerns and
objections of a scientific nature raised by the other Member States and the responses of the applicant.
The NF that is the subject of the application is synthetic L-ergothioneine (ET; marketed as
Ergoneine®), which is produced by a one-pot patented manufacturing process. Chemically, ET is a
derivative of thiolhistidine, i.e. 2-thio-L-histidine-betaine. ET is naturally present in a number of
foodstuffs such as mushrooms, some varieties of black and red beans, offal and cereals.
The production process applied in order to obtain the NF, i.e. synthetic ET, is sufficiently described
and does not raise concerns about the safety of the NF. The information provided on the composition,
specifications, batch-to-batch variability and stability of the NF is sufficient and does not raise safety
concerns.
The applicant intends to use the NF in quantities of up to 5 mg per serving in alcohol-free
beverages, cereal bars, milk, fresh dairy products and chocolate. The applicant also proposes to
provide the NF as a food supplement, with a recommended daily dose of up to 30 mg/day for adults
and 20 mg/day for children. The target population proposed by the applicant is children above 3 years
of age and the general adult population, with the exception of pregnant and breastfeeding women.
The combined intake of ET from all sources (including the background diet) is unlikely to exceed
1.7 mg/kg body weight (bw) per day for adults and 3.7 mg/kg bw per day for children. Taking into
account the intended use levels, the Panel considers that the consumption of the NF is not nutritionally
disadvantageous.
ET is absorbed from food in the gastrointestinal tract via a specific transporter, the organic cation
transporter novel type 1 (OCTN1), also named ergothioneine transporter (ETT). Tissue concentrations
are tightly regulated by this transporter, which is reflected by control of uptake in the small intestine,
selective uptake into tissues and control of re-uptake in the kidney.
Based on the genotoxicity tests provided, the Panel concludes that there are no concerns regarding
genotoxicity of the NF. Two subchronic toxicity studies in Sprague–Dawley rats were provided, which
were carried out with the NF that is the subject of the application and with another synthetic ET
(purity > 99%), respectively. Based on the observations from both these studies, the Panel considers
that the no observed adverse effect level (NOAEL) of the NF is 800 mg/kg bw per day.
Concerns had been raised by the Member States on the possible role of ET in relation to several
health outcomes, in particular diabetes mellitus and inflammatory diseases such as Crohn’s disease
(CD) and rheumatoid arthritis (RA). The Panel considers that from the available human studies no
relationships can be inferred with regard to dietary or supplemental ET and the susceptibility to or
development of diabetes mellitus, CD or RA.
With regard to allergenicity, the Panel considers that the likelihood of adverse reactions to the NF is
low.
Considering the NOAEL of 800 mg/kg bw per day, and the maximum estimated intake levels of ET
from all sources (i.e. fortified foods, food supplements, background diet) of 1.7 mg/kg bw per day for
adults and of 3.7 mg/kg bw per day for children, the Panel concludes that the margins of safety of 470
for adults (except pregnant and breastfeeding women) and of 216 for children above 3 years of age
are sufficient.
The Panel concludes that the NF, synthetic ET (marketed as Ergoneine®), is safe under the
intended conditions of use as specified by the applicant.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 25 July 2013, the company Tetrahedron submitted a request under Article 4 of the Novel
Food Regulation (EC) No 258/971 to place on the market synthetic L-ergothioneine (ET) as a novel
food.
On 19 February 2015, the competent authority of France forwarded to the Commission its initial
assessment report, which came to the conclusion that synthetic ET meets the criteria for acceptance of
a novel food defined in Article 3(1) of Regulation (EC) No 258/97.
On 9 March 2015, the Commission forwarded the initial assessment report to the other Member
States. Several of the Member States submitted comments or raised objections.
The concerns of a scientific nature raised by the Member States (MS) can be summarised as
follows:
• The maximum amounts indicated in the specifications for the solvent residues methanol,
ethyl acetate, isopropanol and ethanol comply with the European Pharmacopoeia. However,
the specifications should be derived from the actual concentrations of the solvents in the
product in question, which are considerably lower than the parameters as stated in the
specifications.
• One MS considered that ET, when used as a food ingredient, might be a possible contributing
factor to inflammatory diseases. In particular in view of the fact that some European countries
have seen an increase in the incidence of inflammatory bowel diseases (IBDs) (Vind et al.,
2006).
• Some MS criticised the combined subchronic/reproductive and developmental toxicity study, in
particular the fact that only five male and five female animals (instead of 10 of each) were
tested in the haematological, clinical-chemical and urine analyses, which may have reduced the
likelihood of identifying toxicologically relevant effects.
• More information was requested on the pharmacokinetics (absorption distribution metabolism
and excretion (ADME)) of the NF, in particular on the mechanism leading to the plateau level in
the body.
• More information was requested on the nutritional safety of the novel food in order to assess
whether the novel ingredient creates a nutritional disadvantage, in particular as regards the
effects of the novel food on the bioavailability of various nutrients owing to its capacity to form
complexes with divalent metal cations. It was commented that neither short- nor long-term
effects of the NF have been assessed in humans.
• One MS commented that foodstuffs enriched with ET should not be consumed by babies,
infants or children, as metabolic side-effects from using the product cannot be ruled out, yet.
More information and experience from post-marketing monitoring is needed in respect of these
vulnerable target groups.
• It is unclear whether the testing facilities, which were involved in the chemical and
microbiological analyses of the batches, were accredited to carry out the analysis according to
an internationally recognised system.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20022, the European Food Safety
Authority (EFSA) is asked to carry out the additional assessment for synthetic ET as a novel food in the
context of Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific
nature in the comments raised by the other Member States.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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2. Data and methodologies
2.1. Data
The assessment of the safety of this novel food (NF) is based on data supplied in the original
application, the initial assessment by the competent authority of France, the concerns and objections
of a scientific nature of the other MS and the responses of the applicant.
In accordance with Commission Recommendation 97/618/EC3, synthetic L-ergothioneine (ET) is
allocated to Class 1.2, i.e. ‘foods and food components that are single chemically defined substances
or mixtures of these which are not obtained from plants, animals or microorganisms that have been
genetically modified and whose source has no history of food use in the Community’. The data are
required to comply with the information required for novel foods of Class 1.2, i.e. structured schemes
I, II, III, IX, XI, XII and XIII of Commission Recommendation 97/618/EC. In the current scientific
opinion, these structured schemes are listed in Sections 3.1–3.8. The intention is to add the NF to
alcohol-free beverages, cereal bars, milk, dairy products, chocolate, and to market the NF as a food
supplement. This assessment concerns only the risk that might be associated with consumption of the
NF under the proposed conditions of use, and is not an assessment of the efficacy of the NF with
regard to any claimed benefit.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientific aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
3.1. Specification of the NF
The NF which is the subject of the application is synthetic L(+)-ergothioneine (marketed as
Ergoneine®).
ET is a natural compound which was first isolated in 1909 from rye ergot (Claviceps purpurea). It is
present in a number of foodstuffs such as mushrooms, some varieties of black and red beans
(Phaseolus vulgaris), offal and cereals.
Chemically, ET (CAS No: 497-30-3; formula: C9H15N3O2S) is a derivative of thiolhistidine, 2-thio-
L-histidine-betaine, with a molecular mass of 229.3 Da. Its International Union for Pure and Applied
Chemistry (IUPAC) name is (2S)-3-(2-thioxo-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylammonio)-
propanoate. The chemical structure of ET is indicated in Figure 1.
The specifications for the NF are indicated in Table 1. They include physical and chemical
parameters as well as specifications for residual solvents, contaminants such as heavy metals,
microbiological specifications and impurities.
Figure 1: Chemical structure of L(+)-ergothioneine
3 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientific aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council. OJ L 253, 16.9.1997, p. 1–36.
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In order to confirm that the manufacturing process is reproducible and adequate to produce a
product that is within the specifications as set above, the applicant provided batch-to-batch analyses
(Table 2) of four batches produced on different scales. Batch Nos. 12779 and 12799 were obtained by
pooling and blending 80 g batches manufactured by Tetrahedron. Batch No. 2299 was a pilot batch
manufactured by a provider on an industrial scale in June 2011 and batch No. 2319 was a good
manufacturing practice (GMP) industrial scale batch manufactured by a provider in December 2012.
Table 1: Specifications of the NF
Parameter Specification Method
Appearance White powder Visual
Optical rotation [a]D ≥ (+) 122° (c = 1, H2O)
(a) Polarimetry
Chemical purity ≥ 99.5% HPLC [Eur. Ph. 2.2.29]
≥ 99% 1H-NMR
Identification Compliant with the structure
C: 47.14  0.4%
H: 6.59  0.4%
N: 18.32  0.4%
Elemental analysis
1H-NMR
Total residual solvents (methanol, ethyl
acetate, isopropanol, ethanol)
[Eur. Ph. 01/2008:50400]
< 1,000 ppm
Gas chromatography
[Eur. Ph. 01/2008:20424]
Loss on drying Internal standard < 0.5% [Eur. Ph. 01/2008:20232]
Impurities < 0.8% HPLC/GPC or 1H-NMR
Heavy metals(b)
Lead < 3 ppm ICP/AES
(Pb, Cd)
Atomic fluorescence (Hg)
[Reg. No. 1881/2006/EC](c)
Cadmium < 1 ppm
Mercury < 0.1 ppm
Microbiological specifications(b)
Total viable aerobic count (TVAC) ≤ 1 9 103 CFU/g [Eur. Ph. 01/2011:50104]
Total yeast and mould count (TYMC) ≤ 1 9 102 CFU/g
Escherichia coli Absent in 1 g
Eur. Ph.: European Pharmacopoeia; 1H-NMR: proton nuclear magnetic resonance; HPLC: high-performance liquid
chromatography; GPC: gel permeation chromatography; ICP/AES: Inductively coupled plasma atomic emission spectroscopy;
CFU: colony-forming units.
(a): Lit. [a]D = (+) 126.6° (c = 1, H2O).
(b): Analyses conducted on each batch.
(c): Amended by Reg. No. 629/2008/EC.
Table 2: Batch-to-batch analyses of the NF
Parameter Specification
Batch results
No. 12779 No. 12799 No. 2299 No. 2319
Appearance White powder Compliant Compliant Compliant Compliant
Optical rotation [a]D ≥ (+) 122°
(c = 1, H2O)
+ 122.2 + 123.5 + 124.4 + 126.0
Chemical purity HPLC ≥ 99.5% 99.9% 99.9% 99.6% 99.9%
1H-NMR ≥ 99% ≥ 99% ≥ 99% ≥ 99% ≥ 99%
Impurities < 0.8% Compliant Compliant Compliant Compliant
Identification 1H-NMR Compliant Compliant Compliant Compliant
Elemental analysis
C: 47.14  0.4% 47.00 47.20 47.24 46.99
H: 6.59  0.4% 6.55 6.39 6.50 6.46
N: 18.32  0.4% 18.20 18.52 18.32 18.20
Total residual solvents < 1,000 ppm Compliant Compliant Compliant Compliant
Loss on drying < 0.5% – – 0.1% 0.1%
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The Panel considers that the information provided on the composition, the specifications and the
batch-to-batch variability of the NF is sufficient and does not raise safety concerns.
3.1.1. Stability of the NF
The applicant provided the results of a stability study performed with three batches under
intermediate testing conditions (30  2°C, 65  5% relative humidity (RH)) up to 12 months and
accelerated testing conditions (40  2°C, 75  5% RH) up to 6 months. The analyses submitted
indicate that the NF remains within specifications and is expected to remain stable under normal
storage conditions for at least 1 year. The recommended storage temperature is 2–8°C.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF.
3.2. Effect of the production process applied to the NF
The synthesis of the NF is a one-pot reaction and is based on a patent (FR0956962), which is
described in the publication by Erdelmeier et al. (2012). The production process complies with the
standards for GMP. Comprehensive information on the manufacturing process (confidential) was
provided by the applicant.
The synthesis of ET is performed in water and includes the following steps. First, L-hercynine is
reacted with bromine and then with cysteine. The intermediate obtained is transformed into ET by
heating in the presence of mercaptopropionic acid. Finally, the raw product is purified by
crystallisation.
The Panel considers that the production process is sufficiently described and does not raise
concerns about the safety of the NF.
3.3. History of the organism used as the source of the NF
The NF which is the subject of the application is synthetically produced ET and it is thus not
obtained from a biological source. Therefore, this section is not applicable for the NF under evaluation.
3.4. Anticipated intake/extent of use of the NF
The applicant intends to use the NF in quantities of up to 5 mg per serving in the following food
groups: alcohol-free beverages 25 mg/kg (200 mL serving); cereal bars 200 mg/kg (25 g serving);
milk 25 mg/kg (200 mL serving); fresh dairy products, such as cream, cream cheese and yoghurt
40 mg/kg (125 g serving); chocolate 250 mg/kg (20 g serving). These values represent the maximum
use levels in the specified food groups.
The applicant also proposes to provide the NF as a food supplement, with a recommended daily
dose of up to 30 mg/day for adults and 20 mg/day for children.
The target population proposed by the applicant is children above 3 years of age and the general
adult population, with the exception of pregnant and breastfeeding women.
Parameter Specification
Batch results
No. 12779 No. 12799 No. 2299 No. 2319
Heavy metals
Lead < 3 ppm Compliant Compliant Compliant Compliant
Cadmium < 1 ppm Compliant Compliant Compliant Compliant
Mercury < 0.1 ppm Compliant Compliant Compliant Compliant
Microbiological specifications
Total viable aerobic count
(TVAC)
≤ 1 9 103 CFU/g ≤ 10 CFU/g ≤ 10 CFU/g – ≤ 10 CFU/g
Total yeast and mould
count (TYMC)
≤ 1 9 102 CFU/g ≤ 10 CFU/g ≤ 10 CFU/g – ≤ 10 CFU/g
Escherichia coli Absent in 1 g Compliant Compliant – Compliant
HPLC: high-performance liquid chromatography; 1H-NMR: proton nuclear magnetic resonance; CFU: colony-forming units.
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3.4.1. Intake from fortified foods
The applicant provided intake estimates for the French population (for adults and children) based
on the INCA 2 consumption survey (AFSSA, 2009) as well as estimates for the European population
(for adults) using the EFSA Concise Food Consumption Database.
When using summary statistics from the EFSA Concise Food Consumption Database, the
estimated mean intakes (for adults) from fortified foods ranged from 0.23 (Sweden) to 1.26
(Iceland) mg/kg body weight (bw) per day, and the high (95th percentile) intakes ranged from 0.43
(Sweden) to 3.31 (Iceland) mg/kg bw per day. The Panel notes that in these intake estimates the
food group ‘cereals’ was the greatest contributing food group, and that cereals as such are not
proposed to be fortified but only ‘cereal bars’, which might have resulted in a gross overestimation
of intake.
The applicant also submitted an intake estimate based on data from the INCA 2 consumption
survey from France (AFSSA, 2009). In order to estimate high level intakes, the applicant considered
the 95th percentile of consumption of the two main food categories (adults: alcohol-free beverages
and milk; children: alcohol-free beverages and chocolate) for the population of consumers, plus the
mean consumption of the other food categories considering the total population. This intake estimate
resulted in mean and high level intakes of 0.204 and 0.545 mg/kg bw per day, respectively, for adults,
and 0.600 and 1.179 mg/kg bw per day, respectively, for children (3–17 years).
3.4.2. Intake from the background diet
The main dietary sources of ET are mushrooms, certain varieties of black and red beans, offal and
cereals (Dubost et al., 2007a; Dubost et al., 2007b; Ey et al., 2007). The foods with the highest ET
content are mushrooms, and in particular Boletus edulis (528 mg ET/kg wet weight) and
Pleurotus ostreatus (119 mg ET/kg wet weight) (Ey et al., 2007), which are widely consumed in
Europe. Mushrooms account for about 95% of ET intake via the diet. For this reason (and owing to
the lack of detailed intake data for mushrooms throughout Europe), the intake estimate provided by
the applicant was mostly based on data from an EFSA evaluation on the presence of nicotine in wild
mushrooms (EFSA, 2009).
The highest chronic exposure among adults was found for Italy, with a mean and high (95th
percentile) consumption of 0.06 and 0.48 mg/kg bw per day, respectively, for the total population, and
a mean and high consumption of 0.22 and 0.70 mg/kg bw per day, respectively, for consumers. Also
for the population of children, the highest chronic exposure was found for Italy, with a mean and high
consumption of 0.06 and 0.64 mg/kg bw per day, respectively, for the total population, and a mean
and high consumption of 0.41 and 1.110 mg/kg bw per day, respectively, for consumers.
These values are in line with a recent publication by Ramirez-Martinez et al. (2016) who assessed
the intake of ET in a number of European countries (adults: Belgium, Finland, France, Ireland, Italy;
children: Belgium and Italy). According to this study, the mean chronic dietary intake of ET in the
investigated countries ranges from 0.051 to 0.255 mg/kg bw per day for adults (for consumers), and
from 0.306 to 0.409 mg/kg bw per day for children (for consumers). The high (95th percentile) intake
of ET in consumers ranges from 0.203 (FR) to 0.660 (IT) mg/kg bw per day for adults, and from
1.017 (BE) to 1.110 (IT) mg/kg bw per day for children.
3.4.3. Combined intake from all sources
Considering all sources, in adults, the combined intake of high consumption of the NF from fortified
foods (0.545 mg/kg bw per day) plus high consumption of natural ET from the background diet
(0.70 mg/kg bw per day) plus intake via food supplements (0.43 mg/kg bw per day (i.e. 30 mg/70 kg))
results in a maximum ET intake of 1.68 mg/kg bw per day.
In children, the combined intake of high consumption of the NF from fortified foods (1.179 mg/kg
bw per day) plus high consumption of natural ET from the background diet (1.110 mg/kg bw per day)
plus intake via food supplements (1.429 mg/kg bw per day (20 mg/14 kg – 5th percentile bw for the
age group of children from 3 to 10 years (EFSA Scientific Committee, 2012))) amounts to a maximal
ET intake of 3.72 mg/kg bw per day.
The Panel notes that the above values represent conservative estimates, which likely overestimate
the actually expected intakes of ET from all sources.
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3.5. Nutritional information on the NF
Concerns were raised by some MS in particular as regards potential effects of the NF on the
bioavailability of various nutrients owing to the capacity of ET to form complexes with divalent metal
cations.
The applicant was requested to provide more information/studies on the chelating ability of the NF,
and to which extent and in which direction putatively formed chelates might influence absorption and
bioavailability of nutrients. In reply, the applicant acknowledged the ability of ET to form complexes
in vitro with divalent metal cations, such as Zn2+ and Cu2+, respectively, and that this ability was
found comparable to that of glycine and histamine, a compound structurally similar to ergothioneine
(Hanlon, 1971). However, this chelating ability was not associated with an inhibition of zinc or copper
enzymes from mammals (Hanlon, 1971). The applicant also informed that no data were available
regarding the significance of metal chelates of ET and the relevance of their effects in vivo that could
in particular influence absorption and bioavailability of these metals or other nutrients. Finally, the
applicant pointed out that, with regard to zinc, in the submitted reproductive toxicity study (CiToxLAB
France, 2013b; Forster et al., 2015) no significant effect was observed on mating, reproductive
performance, fertility and offspring development, biological parameters that could be altered by zinc
deficiency.
Taking into account the intended use levels, the Panel considers that the consumption of the NF is
not nutritionally disadvantageous.
3.6. Microbiological information on the NF
The applicant indicated that the risk of microbiological contamination of the NF during production
or storage is low. Nonetheless, regular controls are carried out to verify the microbiological quality of
the NF in compliance with the specifications (see Section 3.1) and in compliance with the standards of
the European Pharmacopoeia (Eur. Ph. 01/2011:50104). The analytical results of such testing were
provided for three batches (Table 2), which showed compliance with the specifications.
The Panel considers that the microbiological information provided does not raise safety concerns.
3.7. Toxicological information on the NF
3.7.1. Absorption, distribution, metabolism and excretion (ADME)
3.7.1.1. Absorption
ET is absorbed from food in the gastrointestinal tract via a specific transporter, the organic cation
transporter novel type 1 (OCTN1) (Gr€undemann et al., 2005; Kato et al., 2010). Due to its specificity
for ET, it is also called L-ergothioneine transporter (i.e. ETT).
After a single oral administration of 330 lg 3H-ET/kg bw to mice, levels of radioactivity in plasma
rapidly increased and then stayed constant for about 10 days. Levels of radioactivity in whole blood
increased more slowly and then stayed constant as well (Kato et al., 2010).
In the 90-day feeding study with Sprague–Dawley rats described under 3.7.4 (CiToxLAB France,
2012; Forster et al., 2015), plasma concentrations were measured. Samples from control animals were
below the limit of quantification for ET (1,000 ng/mL). Plasma levels increased with dose level, but
were not proportional to the administered doses, suggesting saturation of uptake mechanisms of the
absorbed ET. Mean plasma concentrations in weeks 12/13 were lower than those in week 2.
In the subchronic study by Marone et al. (2016, see Section 3.7.4) in Sprague–Dawley rats with
administration via gavage, plasma values of controls were 1,602 ng/mL for males and 2,484 ng/mL for
females, i.e. higher than in the study by CiToxLAB (2012). There was also a different pattern
concerning dose; after 90 days, there was a proportional increase in plasma levels of ET with dose and
the levels were significantly higher than baseline levels of ET. Compared with the study by CiToxLAB
(2012), ET levels were somewhat higher (6,090 and 7,997 ng/mL for males and females dosed
400 mg/kg bw per day compared to approximately 5,500 and 3,500 ng/mL for males and females
dosed 615 and 725 mg/kg bw per day, respectively).
In a human study (Toh et al., 2014) in 10 healthy adult Chinese men, three meals with or without
250 g shiitake mushrooms containing 264 mg ET/kg mushrooms (198 mg ET/day) were consumed
and the following day (in the morning) ET levels in plasma were measured. The median plasma
concentrations were 172 ng/mL without mushroom meal and 425 ng/mL with mushroom meal.
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In another human study (Weigand-Heller et al., 2012), the bioavailability of ET from mushrooms
after consumption of a meal containing 0, 4.4 or 8.8 mg ET in dried mushroom powder (0, 8 and 16 g
Agaricus bisporus) was measured in erythrocytes from 10 healthy men. ET was increased in
erythrocytes within 1–6 h from 3.4 mg/100 mL (34 lg/mL) slightly by 0.1–0.2 mg/100 mL blood
(1–2 lg/mL). The difference to the control was only statistically significant (p < 0.05) for 8.8 mg ET
after 2 h. The difference between the two dose levels was small. The mushroom powder with 4.4 mg
ET corresponded, according to the authors, to a normal mushroom serving (however without
specifying the serving size).
3.7.1.2. Distribution
According to several animal studies, highest ET concentrations occur in the liver, red blood cells and
kidney. Kato et al. (2010) examined the distribution of radioactivity after oral administration of 3H-ET at
a concentration of 330 lg/kg bw in mice. Highest concentrations of radioactivity were observed in the
upper and middle parts of the small intestine at 4 h after oral administration. After 14 days, the
pattern had changed and high levels of radioactivity were found in the liver > kidney > erythrocytes >
intestine. Compared to plasma, much higher concentrations of radioactivity were detected in
erythrocytes.
In studies with rats (Wolf et al., 1961), a similar tissue distribution was observed, i.e. 4–5 h after
intraperitoneal (i.p.) injection of 14C-ET (dose only provided in lCi) 20–30% of the radioactivity was
detected in the liver. The majority was in the non-protein fraction. Similarly, 24 h after intravenous
injection of 3H-ET (dose only provided in lCi) to rats highest levels of radioactivity were found in the
liver > kidney > spleen > lung > blood > testis > plasma (Mayumi et al., 1978). Ten to 19 days after
oral application of 35S-ET (250 mg within 21 day via drinking water) to rats, highest levels of
radioactivity were found in the liver, followed by the blood cells and kidney (Heath, 1953).
The OCTN1/ETT transporter is responsible for the selective uptake of ET into different tissues. Its
role has been demonstrated with OCTN1 knockout mice compared to wild-type mice (Kato et al., 2010),
by analysing OCTN1 transporter mRNA levels in rats (Wu et al., 2000) and in different human tissues
(Gr€undemann et al., 2005; Taubert et al., 2009; Gr€undemann, 2012). The transporter is highly specific
for ET, and its amino acid sequence is well preserved between different species (Gr€undemann, 2012),
but there are species differences in expression profiles within different tissues (Nikodemus et al., 2011;
Gr€undemann, 2012).
The metabolic turnover rate of ET in various organs is low. Mayumi et al. (1978) found that ET
concentrations in blood and in the liver increased in rats linearly during daily i.p. injection of 16 mg
ET/kg bw for 1 week. In addition, ET was not or only to a minor degree eliminated from the liver or
erythrocytes during a fasting period of 1 week (Mayumi et al., 1978) or 2 weeks (Kawano et al.,
1982). Similarly in 10 Chinese male subjects plasma levels increased with dose and duration of ET
administration (0, 5, and 25 mg/day for 7 days). The levels slowly decreased in the subsequent
4 weeks, while ET concentrations in whole blood continued to increase and plateaued at about
4 weeks (Cheah et al., 2016a).
In rats, ET concentrations in the liver increased with age with a maximum at 11 weeks (Kawano
et al., 1982). Similarly ET increases with age in erythrocytes, both in rats (Mackenzie and Mackenzie,
1957) and humans (Kumosani, 2001). In female rats, it increased twofold between the first and third
month of life and then remained constant, while in male rats levels increased during, and up to,
18 months (Mackenzie and Mackenzie, 1957). In a cohort of 205 men, the maximum ET level in
erythrocytes was at 18 years, then it stayed constant, although somewhat higher levels were reported
for the age group > 51 years (Kumosani, 2001). A decline with age (from < 65 to > 75 years), was
found by Cheah et al. (2016b) in an elderly (> 55 years of age) cohort (n = 136, 68% female), both
for levels in whole blood and in plasma. Accordingly, in the investigation by Sotgia et al. (2014) in a
cohort of 439 subjects (age 55–85 years), plasma levels decreased with age.
The ET content in human erythrocytes determined by high-performance liquid chromatography
(HPLC) ranges from about 1.5–4 mg/100 mL (corresponding to 15–40 lg/mL) (Kumosani, 2001;
Kato et al., 2010; Weigand-Heller et al., 2012). There are also several earlier measurements available
(summarised by Cheah and Halliwell, 2012), which are quite similar to those described above. As in
the animal experiments described above (Mayumi et al., 1978; Kato et al., 2010), ET concentrations in
human erythrocytes are about 100-fold higher than in plasma (Chaleckis et al., 2014; Sotgia et al.,
2014; Cheah et al., 2016a). The median ET plasma concentration in the study by Sotgia et al. (2014)
was 1.01 lmol/L (corresponding to 23.2 lg/100 mL or 232 ng/mL). The concentration was not
affected by gender or by the presence of chronic medical conditions.
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3.7.1.3. Metabolism
After i.p. injection in rats, Wolf et al. (1961) identified herzynine (N,N,N-trimethylhistidine) as main
metabolite of ET in the liver, plasma and urine (80% in the liver) indicating a loss of the thiol group
during metabolism.
In a human metabolome analysis (Chaleckis et al., 2014), besides ET, herzynine and S-methyl-ET
were detected in plasma and in red blood cells. These metabolites were also detected in a recent
human study in whole blood and plasma after 0, 5, and 25 mg ET/day for 7 days (Cheah et al.,
2016a). In addition, low amounts of ET sulfonate were found by Chaleckis et al. (2014).
Servillo et al. (2015) investigated the products of ET oxidation produced by neutrophils (from six
healthy volunteers) during oxidative burst and in addition, the oxidation products of the reaction of ET
with hypochlorite in cell-free solutions. Based on the metabolites identified, the following reactions
were proposed: first, the ET disulfide is formed. ET disulfide then hydrolyses to ET sulfenic acid and
ET. ET sulfenic acid then disproportionates into ET sulfinic acid and ET. ET sulfinic acid finally
decomposes into herzynine and sulfurous acid, which is further oxidised to sulfate.
3.7.1.4. Excretion
After i.p. injection to rats, within 4.5 h 51% of the 14C-ET dose was excreted in the urine, 1/3 as
ET, 1/3 as herzynine and 1/3 as unknown metabolites. Only 0.14% of the dose was detected as CO2 in
the breath (Wolf et al., 1961). Heath (1953) detected in addition 35% free sulfate in the urine after
oral administration of 35S-ET to rats. In faeces, only traces of radioactivity were found.
Kato et al. (2010) detected about 10% of the dose as ET in the urine of mice within 14 days after
oral administration. According to ex vivo experiments with kidney cells, ET may be reabsorbed in the
kidney via the OCTN1 transporter (Kato et al., 2010), thus reducing excretion of ET. Accordingly, with
OCTN1 knockout mice, excretion of ET in the urine was considerably enhanced.
In a human study (Cheah et al., 2016a), during 7 days of a daily dose of 0, 5 or 25 mg ET and in
28 days post-exposure, ET, S-methyl-ergothioneine and herzynine were detected in the urine. Levels of
ET and S-methyl-ergothioneine dependently increased during exposure and then gradually declined.
Levels of herzynine were neither dose nor duration dependent, indicating that there are other sources
of herzynine than the actual exposure to ET.
Overall, the Panel notes that tissue concentrations are tightly regulated by the ET transporter,
which is reflected by control of uptake in the small intestine, selective uptake into tissues and finally
control of re-uptake in the kidney. There is no proportional increase with dose or duration in several
studies. The Panel notes that there is no information on the overall percentage of the dose absorbed
and excreted.
3.7.2. Genotoxicity
A bacterial reverse mutation test (Vivotecnia, 2013), which was in compliance with the OECD Test
Guideline (TG) 471, was provided by the applicant. This study was conducted with four strains of
Salmonella Typhimurium (TA98, TA100, TA1535, TA1537) and one strain of Escherichia coli (WP2
(pKM101)) in the presence or absence of a metabolic activation system (S9 mix). The ET
concentrations (batch No. 2299, > 99% purity) used in this Ames test were determined by a
preliminary toxicity study conducted on S. Typhimurium strain TA100. Under the experimental
conditions (0.06–5.0 mg/well), no significant increase in the number of mutant colonies was observed
for any strain (in the presence or absence of the metabolic activation system).
A further Ames test (Schauss et al., 2010) was carried out with a commercial synthetic ET,
EGTTM (obtained from Oxis International; > 99% pure as assessed by HPLC and chiral HPLC). The test
(in compliance with the OECD TG 471) with the S. Typhimurium strains TA98, TA100, TA1535 and
TA1537 as well as E. coli WP2 uvrA was negative with and without S9 mix.
Furthermore, another Ames test (Marone et al., 2016) carried out with another commercial
synthetic ET, i.e. Mironova EGT+ (manufactured by Mironova Labs Inc., purity > 99%), performed with
the same tester strains as mentioned above, was also negative with and without S9 mix.
In an in vitro chromosomal aberration test with V79 cells (in compliance with the OECD TG 473;
Schauss et al., 2011) in the presence and absence of S9 mix no increases in the number of cells with
structural chromosome aberrations were observed up to a concentration of 5,000 lg/mL ET, which
was slightly cytotoxic. This test as well as the following one were performed with synthetic ET (EGTTM,
> 99% pure) from Oxis International.
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In an in vivo micronucleus test (in compliance with the OECD TG 478; Schauss et al., 2011), with
up to 1,500 mg/kg bw ET (i.e. EGTTM) no increases in the number of micronuclei was observed 24 and
48 h after application of the test substance. The proportion of polychromatic to normochromatic
erythrocytes was not decreased. As several studies showed the presence of ET in plasma and
erythrocytes, it can be considered that the bone marrow is reached by the test substance.
Based on the information provided, the Panel concludes that there are no concerns regarding
genotoxicity of the NF.
3.7.3. Acute toxicity studies
An acute oral toxicity study (CiToxLAB France, 2013a; Forster et al., 2015) was conducted (in
compliance with the good laboratory practice (GLP) and OECD TG 423) in six nulliparous female
Sprague–Dawley rats. The test substance (batch No. 2299, > 98% purity) was administered by gavage
at a dose level of 2,000 mg/kg bw (the test dose was selected on the basis of the toxicological data
available). During the 14-day observation period, no death occurred and the animals did not present
with any clinical sign. One animal out of the six tested presented with weight gain that was less than
normal over the second week of observation. In contrast, one animal presented with weight gain that
was greater than normal during the same period. However, the relationship between animal body
weight and the test substance was not established. Two animals presented with red discoloration of
the thymus during the gross autopsy examination. These findings were not considered as related to
the test substance.
Under the above experimental conditions, the median lethal dose (LD50) of synthetic ET was
greater than 2,000 mg/kg bw.
3.7.4. Subacute and subchronic toxicity studies
A 2-week subacute toxicity study (CiToxLAB France, 2012; Forster et al., 2015) was conducted in
six male and six female rats, which were administered feed containing ET (batch No. 2299, > 99%
purity) in various amounts, i.e. 0% (control), 0.3%, 0.5% or 0.9%. The plasma concentrations of ET
were found to be increased in all the animals which were given ET. On the basis of the findings of this
investigation, the highest administered concentration of 0.9% was chosen as a suitable maximum
concentration for a study with longer exposure.
A subchronic toxicity study (CiToxLAB France, 2013b; Forster et al., 2015) was submitted that was
combined with a screening test for reproductive and developmental toxicity (based on the OECD TG
422 and 408). Groups of Sprague–Dawley rats, 10 males and 10 females in each, were given feed with
ET (batch 2299, > 99% purity, from Tetrahedron, France). ET was administered via feed in
concentrations of 0% (control), 0.3%, 0.5% or 0.9% to the male animals 10 weeks prior to mating
and during mating (up to 3 weeks), for a total of at least 13 weeks. The female animals were treated
13 weeks prior to mating, during mating (up to 3 weeks) and during the gestation and lactation
periods up until the fifth day post-partum. Five male and five female animals per dose group were
examined for the endpoints of the repeated dose toxicity study. No substance related findings were
observed concerning any of the parameters tested. The maximum concentration that was tested in the
feed, equivalent to a dose of 614.9 mg/kg bw per day for male animals and 725 mg/kg bw per day for
female animals, can therefore be considered as the NOAEL.
Another synthetic ET, i.e. Mironova EGT+ (purity > 99%), was tested in a preliminary 28 day study
and in a subchronic toxicity study (Marone et al., 2016), according to the OECD TG 407 and TG 408.
In the subchronic study, Sprague–Dawley rats (10 per sex and dose group) were daily exposed to 0,
400, 800 and 1,600 mg/kg bw per day ET via gavage in distilled water. Only at the highest dose level
of 1,600 mg/kg bw per day the following statistically significant findings were reported: (i) changes in
haematology and coagulation parameters for both males (absolute monocytes counts and prothrombin
time) and females (haemoglobin, haematocrit, mean corpuscular volume, red cell width, absolute
eosinophil and reticulocyte count and prothrombin time); (ii) serum chemistry changes in males
(alkaline phosphatase, glucose, sodium and chloride) and females (alkaline phosphatase, creatinine,
albumin, total protein and triglycerides) (with the exception of the absolute eosinophilic levels in high-
dose females, all values were within historical control values); (iii) decreased absolute and relative
thymus weights, increased relative kidney and liver weights only in females. The Panel considers that
the number of effects observed at the highest dose may indicate first signs of toxicity in the
haematopoietic system, liver and kidney, where the highest ET concentrations are found. The
Panel therefore considers as the NOAEL the dose level of 800 mg/kg bw per day, which is supported
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by the absence of effects at a similar dose level in the study provided by the applicant (CitoxLAB
France, 2013b; Forster et al., 2015).
3.7.5. Reproductive toxicity
As described under Section 3.7.4, a combined repeated dose reproductive toxicity study with rats
was provided by the applicant (CiToxLAB France, 2013b; Forster et al., 2015), which was based on the
OECD TG 422 and TG 408. There were no effects of ET treatment on any parameter of reproductive
or developmental toxicity. The NOAEL therefore is the maximum concentration that was tested in the
feed, equivalent to a dose of 614.9 mg/kg bw per day for male animals and 725 mg/kg bw per day for
female animals.
3.7.6. Human studies
The applicant provided one placebo-controlled, double-blind study (Cheah et al., 2016a), in which
47 healthy Chinese males were randomised to consume a daily dose of 0, 5 or 25 mg ET for 7 days
and were followed up to 28 days post-exposure. Apart from the uptake of ET and its pharmacokinetics
(described in Section 3.7.1), putative effects of ET on some biomarkers of oxidative damage (protein
carbonyls, F2 isoprostanes), allantoin, 8OH-deoxyguanosin (8OHdG) and inflammation (C-reactive
protein) were studied. No significant differences were found for these parameters between the study
groups. No adverse effects or apparent side effects were noted throughout the study. No significant
differences were observed in both liver function tests and lipid profiles for the duration of the study.
The Panel notes that although results from this study do not raise safety concerns, no conclusion on
the safety of long-term intake of ET can be drawn.
Apart from the studies in healthy subjects by Kumosani (2001) and Cheah et al. (2016b), which are
described in the ADME Section (3.7.1), the applicant provided studies reporting on ET concentrations in
blood and/or plasma in patients with leukaemia (McMenamy et al., 1960), pre-eclamptic pregnant
women (Turner et al., 2009) and in cataractous lenses (Shukla et al., 1981). The Panel notes that in
these studies ET concentrations in red blood cells were decreased in patients with chronic granulocytic
leukaemia but not in other leukaemic patients compared to normal subjects, were increased in
pre-eclamptic pregnant women compared to normotensive women, and were decreased in cataractous
lenses. The Panel considers that these studies do not inform on the safety of ET and do not allow
inferring conclusions on relationships between ET concentrations and the disease states studied.
Concerns have been raised by the MS as regards a possible effect of ET on glucose homoeostasis.
The Panel notes four studies (Salt, 1931; Fraser and Jegard, 1950; Epand, 1982; Epand et al., 1988)
which reported on ET in diabetic patients.
Salt (1931) determined ET content in blood from healthy subjects (n = 11), diabetics (n = 17),
nephritic patients (n = 14) and patients with miscellaneous diseases (n = 13). A large range of ET values
(given as mg per 100 mL blood corpuscles) was found in all groups. Mean values (ranges) from healthy,
nephritic patients and patients with various pathological conditions were 7.3 (3.1–12), 7.8 (4.9–14.6)
and 7.8 (4–14.7) mg/100 mL, respectively. In the diabetics, the ET content was slightly higher than in
healthy subjects (mean 10.2, range 7–15 mg per 100 mL). There was no correlation between ET and
blood glucose values and neither were ET values related to any stage of the disease or to the treatment.
Fraser and Jegard (1950) determined the ET content in blood from 94 healthy persons (age
29.5 years) and 107 diabetic patients (age 52.1 years). No ET was found in plasma. Mean (SD) ET
level (given as mg/100 mL blood corpuscles) for female and male subjects combined was significantly
higher in subjects with diabetes 12.7 (8.3) than in normal subjects 9.6 (3.1). No relationship was
found between the ET level and the diabetic state of control, duration of diabetes, age, sex, blood
cholesterol, uric acid, and non-protein nitrogen.
Based on the observation that potent chelators of divalent metal ions such as
diphenylthiocarbazone and quinaldic acid are known to be diabetogenic agents, Epand (1982)
hypothesised that ET, which is known to chelate divalent metal ions, may be a contributing factor
leading to the development of diabetes mellitus in some individuals through its chelation of zinc, which
is important for the storage of insulin and glucagon.
Epand et al. (1988) measured ET concentrations in the blood of 113 patients with diabetes mellitus
and 22 non-diabetic individuals. There was no significant difference between the mean ET
concentrations of the diabetic and non-diabetic populations. Within the diabetic population, males had
a higher ET concentration than females; type II diabetics had a higher ET concentration than type I
diabetics; diabetics receiving a higher insulin dose had higher ET concentrations. There was no
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correlation of ET concentration with the concentration of haemoglobin A1 or with the number of years
diabetic. Neither zinc status nor zinc binding of ET was evaluated.
The Panel notes that two studies found enhanced ET concentrations in blood of diabetic patients
compared to non-diabetic controls, whereas another study did not observe such a difference. The
Panel considers that a relationship between ET concentrations in blood and the development of
diabetes cannot be inferred from these studies.
Concerns have been raised by MS in view of the fact that the incidence of inflammatory bowel
diseases has increased in industrialised countries (Vind et al., 2006). One MS considered that there is
insufficient evidence for the safety of ET, which might be a possible contributing factor to inflammatory
diseases, when used as a food ingredient.
The applicant provided several studies that investigated ET and its possible role in relation to
Crohn’s disease (CD) and rheumatoid arthritis (RA), of which six studies (Peltekova et al., 2004;
Taubert et al., 2005, 2009; Leung et al., 2006; Kato et al., 2010; Huff et al., 2012) reported on
possible associations of variants in OCTN1/ETT with the susceptibility to CD.
The Panel notes that mutations in the ET transporter locus, and especially the 503F variant, have
been associated with the susceptibility to CD in Caucasian populations (Peltekova et al., 2004; Taubert
et al., 2005, 2009; Leung et al., 2006; Huff et al., 2012).
In studies with HEK293 fibroblasts transfected with solute carrier family 22 member 4 gene
(SCL22A4, encoding OCTN1/ETT), the 503F variant resulted in a 50% higher initial transport capacity
at low ET levels (Taubert et al., 2005). The Panel notes that based on these results, it was speculated
that carriers of the 503F allele accumulate higher ET concentrations in SCL22A4 expressing cells
compared with carriers of the wild-type 503L allele, and therefore high tissue levels may constitute a
possible risk factor for CD. The Panel notes that no data were provided to prove this hypothesis.
The Panel notes enhanced cell proliferation in the colon cancer epithelial cell line Caco-2 that was
shown to be homozygous for the 503F allele and to express high levels of OCTN1 mRNA in a dose-
dependent manner after exposure to ET concentrations above 20 lmol/L for 24 h (Taubert et al.,
2005). From this result and from the previous finding that levels of SLC22A4 mRNA were upregulated
by pro-inflammatory cytokines, it was suggested that ET may accelerate the inflammatory process by
transcriptional activation of fibroblast repair proliferation, thereby also conferring susceptibility of CD
patients to develop colorectal cancer. The Panel notes that it is unclear how these results in Caco-2
cells translate into in vivo conditions and that no data were provided to prove this hypothesis.
The Panel also notes one study in which mutations reported to be associated with CD patients in
Caucasians (C1672T/L503F in SLC224) were completely absent in Japanese CD patients (Kato et al.,
2010).
The Panel notes that ET levels in peripheral blood mononuclear cells and in intact mucosa were
significantly higher in 503F than in 503L carriers without differences between patients and controls,
and that ET levels were elevated in mucosal biopsies from inflamed segments of CD patients by
twofold compared with adjacent normal mucosa, which correlated with increases in OCTN1 mRNA
(Taubert et al., 2009).
The Panel notes a study (Huff et al., 2012) indicating an increase in frequency of the 503F variant
due to recent positive selection, that disease-causing variants in linkage disequilibrium with 503F have
hitchhiked to relatively high frequency, thus forming the inflammatory bowel disease 5 gene (IBD5)
risk haplotype, and that the CD association at IBD5 does not result from 503F itself, but from a nearby
hitchhiking variant in the interferon regulatory factor 1 gene (IRF1).
The Panel considers that no relationship can be inferred from the above described studies with
regard to dietary or supplemental ET and the susceptibility for CD.
Three studies (Reglinski et al., 1991; Tokuhiro et al., 2003; Taubert et al., 2006) report on a
potential relationship between ET and RA.
The Panel notes that one study (Reglinski et al., 1991) found lower ET concentrations in red blood
cells in RA compared to healthy volunteers, whereas another study (Taubert et al., 2006) reported
increased ET concentrations in RA patients when compared to patients with coronary heart disease or
osteoarthritis. Whether the discrepancy in results might be influenced by the different control groups
used in these studies remains unknown.
The Panel also notes one study (Tokuhiro et al., 2003) indicating that genetic modifications in both
SLC22A4 (the expression of which is usually increased in inflammatory condition) and runt-related
transcription factor 1 gene (RUNX1, encoding a transcription factor that is involved in the regulation of
SLC22A expression and was strongly associated with RA) leading to suppression of the expression of
SLC22A4 may affect susceptibility to RA.
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The Panel considers that no relationship can be inferred from these studies with regard to dietary
or supplemental ET and the susceptibility to RA.
3.8. Allergenicity
The applicant stated that the NF, as a molecule of low molecular weight, would only be allergenic
after binding to a macromolecule (basically protein in nature) or because of proteinaceous
contaminants. However, according to the applicant, the NF has no chemical group capable of reacting
with proteins under physiological conditions. The manufacturing process for the NF does not involve
any raw material that may contain proteinaceous contaminants.
The Panel considers that the likelihood of adverse reactions to the NF is low.
4. Discussion
The NF which is the subject of the application is synthetic ET (marketed as Ergoneine®). Natural
ET is present in a number of foodstuffs such as mushrooms, some varieties of black and red beans,
offal and cereals. Chemically, ET is a derivative of thiolhistidine, i.e. 2-thio-L-histidine-betaine.
The information provided on the composition, the specifications, batch-to-batch variability and the
stability of the NF is sufficient and does not raise safety concerns. The production process is
sufficiently described and does not raise concerns about the safety of the NF.
The applicant intends to use the NF in quantities of up to 5 mg per serving in alcohol-free
beverages, cereal bars, milk, fresh dairy products and chocolate. The applicant also proposes to
provide the NF as a food supplement, with a recommended daily dose of up to 30 mg/day for adults
and 20 mg/day for children. The target population proposed by the applicant is children above 3 years
of age and the general adult population, with the exception of pregnant and breastfeeding women.
The combined intake of ET from all sources (including the background diet) is unlikely to exceed
1.7 mg/kg bw per day for adults and 3.7 mg/kg bw per day for children.
Taking into account the intended use levels, the Panel considers that the consumption of the NF is
not nutritionally disadvantageous.
ET is absorbed from food in the gastrointestinal tract via a specific transporter, the OCTN1/ETT.
Tissue concentrations are tightly regulated by this transporter, which is reflected by control of uptake
in the small intestine, selective uptake into tissues and control of re-uptake in the kidney.
Based on the genotoxicity tests provided, the Panel concludes that there are no concerns regarding
genotoxicity of the NF.
Two subchronic toxicity studies in Sprague–Dawley rats were provided, which were carried out with
the NF that is the subject of the application and with another synthetic ET of high purity, respectively.
Based on the observations from both these studies, the Panel considers that the NOAEL of the NF is
800 mg/kg bw per day.
Concerns had been raised by the MS on the possible role of ET in relation to several health
outcomes, in particular diabetes mellitus and inflammatory diseases such as CD and RA. The
Panel considers that from the available human studies no relationships can be inferred with regard to
dietary or supplemental ET and the susceptibility to or development of diabetes mellitus, CD or RA.
Considering the NOAEL of 800 mg/kg bw per day, and the maximum estimated intake levels for ET
from all sources (i.e. fortified foods, food supplements, background diet) of 1.7 mg/kg bw per day for
adults and of 3.7 mg/kg bw per day for children, the Panel concludes that the margins of safety of 470
(800/1.7) for adults (excluding pregnant and breastfeeding women) and of 216 (800/3.7) for children
above 3 years of age are sufficient.
5. Conclusions
The Panel concludes that the NF, synthetic ET (marketed as Ergoneine®), is safe under the
intended conditions of use as specified by the applicant.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of synthetic L-ergothioneine. Ref. Ares(2015)
4280093, dated 14 October 2015.
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2) On 22 October 2015, EFSA received the following documentation: dossier ‘Tetrahedron
Ergoneine Documentation February confidential’, submitted by Tetrahedron; initial assessment
report carried out by the Food Safety Authority of France: ‘OPINION of the Agence nationale de
securite sanitaire de l’alimentation, de l’environnement et du travail (Anses, Agency for Food,
Environmental and Occupational Health and Safety) on an application for authorisation to place
on the market a novel food ingredient: synthetic L-ergothioneine’. Referral No 2013-SA-0220;
the Member States’ comments and objections; response by the applicant to the initial
assessment report and the Member States’ comments and objections.
3) On 4 December 2015, EFSA sent a request to the applicant to provide missing information to
accompany the application.
4) On 14 December 2015, EFSA received the missing information as submitted by the applicant.
After checking the content of the full dossier, including the missing information, EFSA
considered the application valid as of 11 January 2016.
5) On 14 June 2016, EFSA sent a request to the applicant to provide additional information to
accompany the application.
6) Additional data were provided by the applicant on 26 July 2016.
7) During its meeting on 26 October 2016, the NDA Panel, having evaluated the data, adopted
a scientific opinion on the safety of synthetic L-ergothioneine (Ergoneine®) as a novel food
pursuant to Regulation (EC) No 258/97.
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Abbreviations
8OHdG 8OH-deoxyguanosin
ADME absorption distribution metabolism excretion
bw body weight
CAS Chemical Abstracts Service
CFU colony-forming units
CD Crohn’s disease
DNA deoxyribonucleic acid
ET L(+)-ergothioneine
ETT L(+)-ergothioneine transporter
Eur. Ph. European Pharmacopoeia
GLP good laboratory practice
GMP good manufacturing practice
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
IBD inflammatory bowel disease
ICP/AES inductively coupled plasma/atomic emission spectroscopy;
IRF1 interferon regulatory factor 1
IUPAC International Union for Pure and Applied Chemistry
i.p. intraperitoneal
LD50 median lethal dose
mRNA messenger RNA
MS Member State
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
NOAEL no observed adverse effect level
OCTN1 organic cation transporter novel type 1
OECD Organisation for Economic Co-operation and Development
RA rheumatoid arthritis
Safety of synthetic L-ergothioneine
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2016;14(11):4629
RH relative humidity
RNA ribonucleic acid
RUNX1 runt-related transcription factor 1
SD standard deviation
SLC22A4 solute carrier family 22 member 4
TG Test Guideline
TVAC total viable aerobic count
TYMC total yeast and mould count
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